Alaunos Therapeutics (TCRT) 10-Q 6 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	ZIOP
Entity Registrant Name	ZIOPHARM ONCOLOGY INC
Entity Central Index Key	1,107,421
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		141,962,789

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 84,406	$ 81,053
Receivables	13	21
Prepaid expenses and other current assets	30,469	23,810
Total current assets	114,888	104,884
Property and equipment, net	1,047	843
Deposits	128	128
Other non-current assets	496	493
Total assets	116,559	106,348
Current liabilities:
Accounts payable	1,524	156
Accrued expenses	10,110	9,109
Deferred revenue - current portion	6,389	6,389
Deferred rent - current portion	166	155
Total current liabilities	18,189	15,809
Deferred revenue, net of current portion	36,736	41,528
Deferred rent, net of current portion	14	126
Derivative liabilities	2,350	862
Total liabilities	57,289	58,325
Commitments and contingencies (Note 6)
Preferred stock, $0.001 par value, 30,000,000 shares authorized
Stockholders' deficit:
Common stock, $0.001 par value; 250,000,000 shares authorized; 141,962,789 and 132,376,670 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	142	132
Additional paid-in capital - common stock	619,232	580,567
Accumulated deficit	(699,169)	(657,997)
Total stockholders' deficit	(79,795)	(77,298)
Total liabilities and stockholders' deficit	116,559	106,348
Series 1 Preferred Stock
Current liabilities:
Series 1 preferred stock, $1,200 stated value; 250,000 designated; 116,127 and 106,184 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively; liquidation value of $139.4 million and $127.4 million at September 30, 2017 and December 31, 2016, respectively	$ 139,065	$ 125,321

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	30,000,000	30,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	141,962,789	132,376,670
Common stock, shares outstanding	141,962,789	132,376,670
Series 1 Preferred Stock
Preferred stock, shares authorized	250,000
Preferred stock, stated value	$ 1,200	$ 1,200
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	116,127	106,184
Preferred stock, shares outstanding	116,127	106,184
Preferred stock, liquidation preference	$ 139.4	$ 127.4

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Collaboration revenue	$ 1,598	$ 1,598	$ 4,792	$ 5,264
Operating expenses:
Research and development	11,105	8,975	33,903	148,402
General and administrative	3,571	3,537	10,946	11,058
Total operating expenses	14,676	12,512	44,849	159,460
Loss from operations	(13,078)	(10,914)	(40,057)	(154,196)
Other income (expense), net	175	39	299	102
Change in fair value of derivative liabilities	202	21	(1,292)	21
Net loss	(12,701)	(10,854)	(41,050)	(154,073)
Preferred stock dividends	(4,903)	(3,591)	(13,939)	(3,591)
Net loss applicable to common stockholders	$ (17,604)	$ (14,445)	$ (54,989)	$ (157,664)
Basic and diluted net loss per share	$ (0.13)	$ (0.11)	$ (0.41)	$ (1.21)
Weighted average common shares outstanding used to compute basic and diluted net loss per share	140,632,297	130,496,035	135,689,364	130,347,370

STATEMENTS OF STOCKHOLDERS' DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital Common Stock	Accumulated Deficit	Series 1 Preferred Stock - Mezzanine
Beginning Balance at Dec. 31, 2016	$ (77,298)	$ 132	$ 580,567	$ (657,997)	$ 125,321
Beginning Balance (in shares) at Dec. 31, 2016		132,376,670			106,184
Exercise of employee stock options	$ 99	$ 1	98
Exercise of employee stock options (in shares)	80,000	26,047
Stock-based compensation	$ 6,165		6,165
Restricted stock buy-back at vesting to cover taxes	(1,042)	$ (1)	(1,041)
Restricted stock buy-back at vesting to cover taxes (in shares)		(148,666)
Issuance of common stock, net of commissions and expenses of $2.7 million	47,270	$ 10	47,260
Issuance of common stock net of commissions and expenses of $2.7 million (in shares)		9,708,738
Preferred stock dividends	(13,939)		(13,939)		$ 13,744
Preferred stock dividends (in shares)					9,943
Net loss	(41,050)			(41,050)
Ending Balance at Sep. 30, 2017	$ (79,795)	$ 142	619,232	(699,169)	$ 139,065
Ending Balance (in shares) at Sep. 30, 2017		141,962,789			116,127
Cumulative effect adjustment (Note 3)			$ 122	$ (122)

STATEMENTS OF STOCKHOLDERS' DE6

STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance of common stock, commissions and expenses	$ 2.7

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (41,050)	$ (154,073)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	259	227
Stock-based compensation	6,165	6,094
Preferred stock issued in exchange for a license agreement		118,936
Change in fair value of derivative liabilities	1,292	(21)
Issuance of common stock in a license agreement		87
(Increase) decrease in:
Receivables	8	421
Prepaid expenses and other current assets	(6,660)	(9,611)
Other noncurrent assets	(3)	1
Increase (decrease) in:
Accounts payable	1,368	(194)
Accrued expenses	1,002	(1,542)
Deferred revenue	(4,792)	(5,264)
Deferred rent	(102)	(322)
Net cash used in operating activities	(42,513)	(45,261)
Cash flows from investing activities:
Purchases of property and equipment	(461)	(469)
Net cash used in investing activities	(461)	(469)
Cash flows from financing activities:
Proceeds from exercise of stock options	99	551
Repurchase of restricted common stock	(1,042)	(853)
Repurchase of common stock		(2)
Proceeds from issuance of common stock, net of commissions and expenses of $2.7 million	47,270
Net cash provided by (used in) financing activities	46,327	(304)
Net decrease in cash and cash equivalents	3,353	(46,034)
Cash and cash equivalents, beginning of period	81,053	140,717
Cash and cash equivalents, end of period	84,406	94,683
Supplementary disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Series 1 Preferred Stock
Supplementary disclosure of noncash investing and financing activities:
Issuance of stock		119,045
Payment of dividends in preferred stock	$ 13,939	$ 3,591

STATEMENTS OF CASH FLOWS (Paren

STATEMENTS OF CASH FLOWS (Parenthetical) $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)
Statement of Cash Flows [Abstract]
Common stock commissions and expenses	$ 2.7

Business

Business	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Business	1. Business Overview ZIOPHARM Oncology, Inc., which is referred to herein as “ZIOPHARM” or the “Company,” is a biopharmaceutical company seeking to develop, acquire, and commercialize, on its own or with partners, a diverse portfolio of immuno-oncology therapies. The Company’s operations to date have consisted primarily of raising capital and conducting research and development. The Company’s fiscal year ends on December 31. The Company has operated at a loss since its inception in 2003 and has minimal revenues to date. The Company anticipates that its losses will continue for the foreseeable future. As of September 30, 2017, the Company has approximately $84.4 million of cash and cash equivalents. At September 30, 2017, the Company’s accumulated deficit was approximately $699.2 million. Given its development plans, the Company anticipates its cash resources will be sufficient to fund its operations into the fourth quarter of 2018. The Company will need to raise additional capital, whether through a sale of equity or debt securities, licensing arrangements, asset sales, additional product collaborations or other means, to complete the development and commercialization of its product candidates, to support its ongoing activities and to continue as a going concern. The forecast of cash requirements is forward-looking information that involves risks and uncertainties, and the actual amount of the Company’s expenses could vary materially and adversely as a result of a number of factors including changes in the Company’s business strategy and direction of its research and development efforts, competitive and technical advances, regulatory changes or other developments. The Company has based its estimates on assumptions that may prove to be wrong, and its expenses could prove to be significantly higher than it currently anticipates. Management does not know whether additional financing will be on terms favorable or acceptable to the Company when needed, if at all. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into collaboration or partnership agreements for further development of its product candidates, management may need to curtail its current development efforts and cut operating costs in order to conserve its cash. Based on the forecast, management determined that there is substantial doubt regarding the Company’s ability to continue as a going concern. Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q It is management’s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K 10-K. The interim financial statements do not include all of the information and footnotes required by GAAP for complete financial statements, as allowed by the relevant SEC rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. The results disclosed in the statements of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results to be expected for the full fiscal year. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. The Company’s most significant estimates and judgments used in the preparation of its financial statements are: • clinical trial expenses; • collaboration agreements; • fair value measurements of stock based compensation, warrants and Series 1 preferred stock; and • income taxes Subsequent Events The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. During this period, the Company did not have any material subsequent events that impacted its financial statements or disclosures.

Financings

Financings	9 Months Ended
	Sep. 30, 2017
Text Block [Abstract]
Financings	2. Financings On May 11, 2017, the Company sold in an underwritten public offering an aggregate of 9,708,738 shares of its common stock. The price to the public in the offering was $5.15 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $4.893 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3ASR No. 333-201826)

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies The Company’s significant accounting policies were identified in the Company’s Form 10-K. 10-K. New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued ASU 2014-09, Revenue from Contracts with Customers 2014-09”), In February 2016, the FASB issued ASU No. 2016-02, Leases 2016-02. Leases In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Accounting 2016-09, 2016-09 2016-09, In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments 2016-15, 2016-15 In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows Restricted Cash 2016-18, In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation Scope of Modification Accounting 2017-09, 2017-09

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The Company accounts for its financial assets and liabilities using fair value measurements. The authoritative accounting guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows: • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016 were as follows: ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 79,488 $ 79,488 $ — $ — Liabilities: Derivative liabilities $ (2,350 ) $ — $ — $ (2,350 ) ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 77,120 $ 77,120 $ — $ — Liabilities: Derivative liabilities $ (862 ) $ — $ — $ (862 ) The cash equivalents represent deposits in a short term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. As discussed further in Notes 6 and 9, the Company issued Intrexon Corporation, or Intrexon, 100,000 shares of the Company’s Series 1 preferred stock, a new class of preferred stock authorized by the Company’s board of directors, in consideration of the parties entering into a Third Amendment to Exclusive Channel Partner Agreement, or the 2016 ECP Amendment, amending their existing Exclusive Channel Partner Agreement, effective January 6, 2011 and as amended to date, which the Company refers to as the Channel Agreement, and an Amendment to Exclusive Channel Collaboration Agreement, or the 2016 GvHD Amendment, amending their existing Exclusive Channel Collaboration Agreement, effective September 28, 2015, which the Company refers to as the GvHD Agreement. At June 30, 2016, the Company’s Series 1 preferred stock was valued using a probability-weighted approach and a Monte Carlo simulation model. Additionally, the monthly dividends issued on the outstanding Series 1 preferred stock are valued using the same probability-weighted approach and a Monte Carlo simulation model. However, there is no adjustment or further revaluation after the initial valuation on the Series 1 preferred stock other than required periodic dividends. The Company’s Level 3 financial liabilities consist of a conversion option and a redemption feature associated with the Company’s Series 1 preferred stock issued to Intrexon that has been bifurcated from the Series 1 preferred stock and are accounted for as derivative liabilities at fair value. The preferred stock derivative liabilities were valued using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. See Note 6 for additional disclosures on the 2016 ECP Amendment and 2016 GvHD Amendments and Note 9 for additional disclosure on the rights and preferences of the Series 1 preferred stock and valuation methodology.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Loss per Share	5. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and preferred stock, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potentially dilutive shares of common stock at September 30, 2017 and 2016 consisted of the following: September 30, 2017 2016 Stock options 3,622,335 3,448,070 Unvested restricted stock 1,330,492 1,236,388 Preferred stock 22,398,582 22,564,685 27,351,409 27,249,143 The Series 1 preferred stock automatically converts into shares of common stock upon the date the first approval in the United States of (i) a ZIOPHARM Product, as defined in and developed under the Exclusive Channel Partner Agreement dated as of January 6, 2011 and as amended from time to time, by and between the Company and Intrexon, or (ii) a Product, as defined in and developed under the Exclusive Channel Collaboration Agreement dated September 28, 2015 and as amended from time to time, by and between the Company and Intrexon, or (iii) a Product as defined in and developed under the License and Collaboration Agreement dated March 27, 2015 and as amended from time to time, by and among Intrexon, Ares Trading, S.A. and the Company, is publicly announced. Assuming a conversion event date of September 30, 2017, the Series 1 preferred stock would convert into 22,398,582 shares of common stock using the greater of (i) the volume weighted average closing price of the Company’s Common Stock as reported by the Nasdaq Stock Market, LLC over the previous 20 trading days ending on the conversion event date or (ii) $1.00 per share. See Note 6 and Note 9 for additional disclosure regarding the 2016 ECP Amendment and 2016 GvHD Amendment, valuation methodology and significant assumptions.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Operating Leases Prior to December 31, 2012, the Company entered into an operating lease in New York, NY for office space. In accordance with this agreement, the Company entered into a letter of credit in the amount of $388 thousand, naming the Company’s landlord as beneficiary. In January 2012, the Company amended the lease agreement, adding additional office space. The collateral for the letter of credit is restricted cash and recorded in other non-current On October 17, 2013, the Company entered into a sublease agreement to lease all of its New York office space to a subtenant. The Company remains primarily liable to pay rent on the original lease. The Company recorded a loss on the sublease in the amount of $729 thousand for the year ended December 31, 2013, representing the remaining contractual obligation of $2.3 million, less $1.6 million in payments from its subtenant. The Company continues to maintain the $388 thousand letter of credit in respect of the New York office space and recorded in other non-current Prior to December 31, 2012, the Company entered into separate operating lease agreements for various spaces in a building in Boston, MA. In June 2012, the Company re-negotiated Total rent expense was approximately $177 thousand and $545 thousand for the three and nine months ended September 30 2017, respectively. Total rent expense for the three and nine months ended September 30, 2016 was $109 thousand and $231 thousand, respectively. The Company records rent expense on a straight-line basis over the term of the lease. Accordingly, the Company has recorded a liability for deferred rent at September 30, 2017 and December 31, 2016 of $180 thousand ($166 thousand current and $14 thousand long-term) and $281 thousand ($155 thousand current and $126 thousand long-term), respectively, which is recorded in deferred rent on the balance sheets. License Agreements Exclusive Channel Partner Agreement with Intrexon Corporation for the Cancer Programs On January 6, 2011, the Company entered into the Channel Agreement with Intrexon that governs a “channel partnering” arrangement in which the Company uses Intrexon’s technology to research, develop and commercialize products in which DNA is administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which the Company collectively refers to as the Cancer Program. This Channel Agreement establishes committees comprising representatives of the Company and Intrexon that govern activities related to the Cancer Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property. The Channel Agreement grants the Company a worldwide license to use patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving DNA administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which are collectively referred to as the ZIOPHARM Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of ZIOPHARM Products, and otherwise is non-exclusive. Under the Channel Agreement, and subject to certain exceptions, the Company is responsible for, among other things, the performance of the Cancer Program, including the development, commercialization and certain aspects of manufacturing of ZIOPHARM Products. Intrexon is responsible for establishing manufacturing capabilities and facilities for the bulk manufacture of products developed under the Cancer Program, certain other aspects of manufacturing and costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Intrexon’s patents. Subsequent to the the 2016 ECP Amendment, discussed below, and subject to certain expense allocations and other offsets provided in the Channel Agreement, the Company is obligated to pay Intrexon on a quarterly basis 20% of net profits derived in that quarter from the sale of ZIOPHARM Products, calculated on a ZIOPHARM Product-by-ZIOPHARM Upon termination of the Channel Agreement, the Company may continue to develop and commercialize any ZIOPHARM Product that, at the time of termination: • Is being commercialized by the Company; • Has received regulatory approval; • Is a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or • Is the subject of at least an ongoing Phase 2 clinical trial (in the case of a termination by Intrexon due to an uncured breach or a voluntary termination by the Company), or an ongoing Phase 1 clinical trial in the field (in the case of a termination by the Company due to an uncured breach or a termination by Intrexon following an unconsented assignment by the Company or its election not to pursue development of a Superior Therapy (as defined in the Channel Agreement)). The Company’s obligation to pay 20% of net profits or revenue described above with respect to these “retained” products will survive termination of the Channel Agreement. Exclusive Channel Collaboration Agreement with Intrexon Corporation for Graft-Versus-Host Disease (GvHD) On September 28, 2015, the Company entered into the GvHD Agreement with Intrexon, whereby the Company will use Intrexon’s technology directed towards in vivo The exclusive collaboration, or the GvHD Program, will focus on the pursuit of the following engineered cell therapy strategies, used either separately or in combination, for the targeted treatment of GvHD: (i) the infusion of regulatory T cells expressing membrane-bound and/or soluble interleukin-2 L. lactis interleukin-2 The GvHD Agreement grants the Company a worldwide license to use specified patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products developed under the GvHD Program, or the Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of the Products, and otherwise is non-exclusive. Under the GvHD Agreement, and subject to certain exceptions, the Company is responsible for, among other things, the performance of the GvHD Program, including development, commercialization and certain aspects of manufacturing of the Products. Among other things, Intrexon is responsible for the costs of establishing manufacturing capabilities and facilities for the bulk manufacture of the Products, certain other aspects of manufacturing, costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Intrexon’s patents. The Company paid Intrexon a technology access fee of $10.0 million in cash in October 2015 and will reimburse Intrexon for all research and development costs. Subject to certain expense allocations and other offsets provided in the GvHD Agreement, the GvHD Agreement also provides for equal sharing of the profits derived from the sale of the Products. The Company has determined that the rights acquired in the GvHD Agreement represent in-process During the first 24 months after September 28, 2015, the GvHD Agreement may be terminated by (i) either party in the event of a material breach by the other, except for the failure of the other party to use diligent efforts or to comply with any diligence obligations set forth in the GvHD Agreement and (ii) Intrexon under certain circumstances if the Company assigns its rights under the GvHD Agreement without Intrexon’s consent. Following such twenty-four-month period, Intrexon may also terminate the GvHD Agreement if the Company elects not to pursue the development of the GvHD Program identified by Intrexon that is a Superior Therapy, as defined in the GvHD Agreement. Also following such period, the Company may voluntarily terminate the GvHD Agreement upon 90 days’ written notice to Intrexon. Upon termination of the GvHD Agreement, the Company may continue to develop and commercialize any Product that, at the time of termination: • is being commercialized by the Company, • has received regulatory approval, • is a subject of an application for regulatory approval that is pending before the applicable regulatory authority, or • is the subject of at least an ongoing Phase 2 clinical trial (in the case of a termination by Intrexon due to a Company uncured breach or a voluntary termination by the Company), or an ongoing Phase 1 clinical trial (in the case of a termination by the Company due to an Intrexon uncured breach or a termination by Intrexon following an unconsented assignment by the Company or the Company’s election not to pursue development of a Superior Therapy). The Company’s obligation to pay 20% of net profits or revenue with respect to these “retained” products will survive termination of the GvHD Agreement. Amendment of Collaborations with Intrexon On March 27, 2015, the Company and Intrexon entered into an Exclusive Channel Partner Amendment, or ECP Amendment, amending the Channel Agreement. The ECP Amendment modifies the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement discussed below. Pursuant to the ECP Amendment, the chimeric antigen receptor T cell products to be developed and commercialized pursuant to the Ares Trading Agreement shall be included within the Intrexon/ZIOPHARM collaboration under the Channel Agreement. The ECP Amendment provides that Intrexon will pay to the Company fifty percent of all payments Intrexon receives for upfronts, milestones and royalties under the Ares Trading Agreement. On June 29, 2016, the Company entered into (1) the 2016 ECP Amendment with Intrexon amending the Channel Agreement, and (2) the 2016 GvHD Amendment, amending the GvHD Agreement. The 2016 ECP Amendment reduced the royalty percentage that the Company will pay to Intrexon under the Channel Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of ZIOPHARM Products, calculated on a ZIOPHARM Product-by-ZIOPHARM In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company agreed to issue to Intrexon 100,000 shares of its Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization, and certain other rights, preferences, privileges and obligations (Note 9). License Agreement—The University of Texas MD Anderson Cancer Center On January 13, 2015, the Company, together with Intrexon, entered into a License Agreement, or the MD Anderson License, with The University of Texas MD Anderson Cancer Center, or MD Anderson. Pursuant to the MD Anderson License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel chimeric antigen receptor, or CAR, T cell therapies, non-viral T-cell co-exclusive non-exclusive Pursuant to the terms of the MD Anderson License, MD Anderson received consideration consisting of $50.0 million in shares of the Company’s common stock (or 10,124,561 shares), and $50.0 million in shares of Intrexon’s common stock, in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the announcement of the entry into the MD Anderson License, collectively referred to as the License Shares, pursuant to the terms of the License Shares Securities Issuance Agreement described below. The License Shares were issued to MD Anderson on March 11, 2015, pursuant to the terms of the MD Anderson License. On January 9, 2015, in order to induce MD Anderson to enter into the MD Anderson License on an accelerated schedule, the Company and Intrexon entered into a letter agreement, or the Letter Agreement, pursuant to which MD Anderson received consideration of $7.5 million in shares of the Company’s common stock (or 1,597,602 shares), and $7.5 million in shares of Intrexon’s common stock, in each case based on a trailing 20-day On August 17, 2015, the Company, Intrexon and MD Anderson entered into a research and development agreement, or the Research and Development Agreement, to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year. During the nine months ended September 30, 2017, the Company made payments in the aggregate amount of $9.3 million to MD Anderson compared to $11.3 million during the nine months ended September 30, 2016. The decrease in cash paid to MD Anderson during 2017 is a result of approved expenditures incurred by the Company being deducted from the April and July 2017 payment. As of September 30, 2017, MD Anderson had used $6.2 million to offset costs incurred pursuant to the MD Anderson License and the Research and Development Agreement. The net balance of $29.4 million is included in other current assets at September 30, 2017. The Company’s final payment to MD Anderson is due in January 2018 and the Company will continue to assess the timing and expected use of the funds. The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company and Intrexon shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day non-exclusive case-by-case 180-day In connection with the MD Anderson License and the issuance of the License Shares and the Incentive Shares, on January 13, 2015, the Company and MD Anderson entered into a Registration Rights Agreement, or the Registration Rights Agreement, pursuant to which the Company agreed to file a “resale” registration statement, or the Registration Statement, registering the resale of the License Shares, the Incentive Shares and any other shares of the Company’s common stock held by MD Anderson on the date that the Registration Statement is filed. Under the terms of the Registration Rights Agreement, the Company is obligated to maintain the effectiveness of the Registration Statement until all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions. A prospectus supplement under the Company’s already effective registration statement on Form S-3 No. 333-201826) The Company determined that the rights acquired in the MD Anderson License represented in process research and development with no alternative future use. Accordingly, the Company recorded a charge of $67.3 million to research and development expense in 2015, representing the fair value of the 11,722,163 shares of its common stock on the date the MD Anderson License was executed. Ares Trading License and Collaboration Agreement On March 27, 2015, the Company and Intrexon signed a worldwide License and Collaboration Agreement, or the Ares Trading Agreement, with Ares Trading S.A., or Ares Trading, a subsidiary of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Under the collaboration, Ares Trading has elected two CAR + + opt-in Intrexon is entitled to receive $5.0 million payable in equal quarterly installments over two years for each identified product candidate, which will be used to fund discovery work. The Company is responsible for costs exceeding the quarterly installments and all other costs of the preclinical research and development. For the three and nine months ended September 30, 2017, the Company has expensed $718 thousand and $994 thousand under the Ares Trading Agreement, respectively. Ares Trading paid a non-refundable The Ares Trading Agreement provides for up to $60.0 million in development milestone payments, up to $148.0 million in regulatory milestone payments and up to $205.0 million in commercial milestone payments for each product candidate. Development milestone payments are triggered upon initiation of a defined phase of clinical research for a product candidate. Regulatory milestone payments are triggered upon approval to market a product candidate by the U.S. Food and Drug Administration, or the FDA, or other global regulatory authorities. Commercial milestone payments are triggered when an approved pharmaceutical product reaches certain defined levels of net sales by the licensee. The Ares Trading Agreement also provides for up to $50.0 million of one-time low-teens The term of the Ares Trading Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon 90 days written notice to the Company. The Company considered FASB Accounting Standards Codification 605-25, Multiple-Element Arrangements Patent and Technology License Agreement—The University of Texas MD Anderson Cancer Center and the Texas A&M University System On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) The Company issued options to purchase 50,222 shares outside of the Company’s stock option plans following the successful completion of certain clinical milestones, of which 37,666 shares have vested. The remaining 12,556 shares vested upon enrollment of the first patient in a multi-center pivotal clinical trial i.e. Collaboration Agreement with Solasia Pharma K.K. On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia. Pursuant to the License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use in a pan-Asian/Pacific As consideration for the license, the Company received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific On July 31, 2014, the Company entered into an amendment and restatement of the License and Collaboration Agreement granting Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, the Company will be eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company’s Licensors, as defined in the agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Company’s license agreement with the Licensors. On March 28, 2016, Solasia initiated a multi-center pivotal clinical trial intended to provide substantial evidence of efficacy necessary to support the filing of an application for an NDA for darinaparsin in certain of the territories assigned to Solasia. The initiation of the trial on March 28, 2016 triggered a $1.0 million milestone payment from Solasia to the Company which was received in May 2016. The Company subsequently made an equivalent payment to MD Anderson as the ultimate licensor of darinaparsin (see above). License Agreement with Baxter Healthcare S.A. On November 3, 2006, the Company entered into a definitive Asset Purchase Agreement for indibulin and a License Agreement to proprietary nanosuspension technology with affiliates of Baxter Healthcare S.A. The purchase included the entire indibulin intellectual property portfolio as well as existing drug substance and capsule inventories. One remaining royalty payment of $250 thousand is due in November 2017. The terms of the Asset Purchase Agreement included an upfront cash payment and an additional payment for existing inventory. No payments were made during the nine months ended September 30, 2017 and 2016. Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute On January 10, 2017, the Company announced the signing of a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, for the development of adoptive cell transfer, or ACT,-based immunotherapies genetically modified using the Sleeping Beauty, non-viral SB-engineered

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Collaborations with Intrexon On January 6, 2011, the Company entered into the Channel Agreement with Intrexon (Note 6). A director of the Company, Randal J. Kirk, is the CEO, a director, and the largest stockholder of Intrexon. On February 3, 2015, Intrexon purchased 1,440,000 shares of common stock in the Company’s public offering upon the same terms as others that participated in the offering. On March 27, 2015, the Company and Intrexon entered into a Second Amendment to the Exclusive Channel Partner Agreement amending the Channel Agreement, which is referred to as the ECP Amendment. The ECP Amendment modified the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement, which the Company and Intrexon entered into with Ares Trading, on March 27, 2015. The ECP Amendment provided that Intrexon will pay to the Company 50% of all payments that Intrexon receives for upfronts, milestones and royalties under the Ares Trading Agreement (Note 6). The Amendment also reduces Intrexon’s aggregate commitment under a Stock Purchase Agreement that the parties executed in connection with the initial Channel Agreement to purchase the Company’s common stock from $50.0 million to $43.5 million, which has been satisfied. On June 29, 2015, the Company re-purchased re-purchased On September 28, 2015, the Company entered into the GvHD Agreement with Intrexon, whereby the Company will use Intrexon’s technology directed towards in vivo On June 29, 2016, the Company entered into the 2016 ECP Amendment, with Intrexon, amending the Channel Agreement, and the 2016 GvHD Amendment, amending their existing Exclusive Channel Collaboration Agreement, effective September 28, 2015, which the Company refers to as the GvHD Agreement. The 2016 ECP Amendment reduced the royalty percentage that the Company will pay to Intrexon under the Channel Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of ZIOPHARM Products (as defined in the Channel Agreement), calculated on a ZIOPHARM Product-by-ZIOPHARM In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company issued Intrexon 100,000 shares of its Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization, and certain other rights, preferences, privileges and obligations (Note 9). The holders of the shares of Series 1 preferred stock are entitled to receive a monthly dividend, payable in additional shares of Series 1 preferred stock, equal to $12.00 per preferred share held by such holder per month divided by the stated value of the preferred shares, rounded down to the nearest whole share. During the three months ended September 30, 2017, the Company issued an aggregate of 3,414 shares of Series 1 preferred stock to Intrexon, the holder of all of the outstanding shares of the Company’s Series 1 preferred stock, as monthly dividend payments. The Company recorded such shares of Series 1 preferred stock at a fair value of $4.9 million, which is a component of temporary equity and recorded a gain on the change of the derivative liabilities in the amount of $202 thousand. See Notes 4 and 9 for additional discussion regarding the accounting for and valuation of these derivative financial instruments. During the three months ended September 30, 2017 and 2016, the Company expensed $5.6 million and $4.9 million, respectively, for services performed by Intrexon. During the nine months ended September 30, 2017 and 2016, the Company expensed $16.8 million and $17.0 million, respectively, for services performed by Intrexon. As of September 30, 2017 and December 31, 2016, the Company recorded $5.5 million and $3.4 million, respectively, in current liabilities on its balance sheet for amounts due to Intrexon. Collaboration with Intrexon and MD Anderson On January 13, 2015, the Company, together with Intrexon, entered into a license agreement with MD Anderson, which is referred to as the MD Anderson License. Pursuant to the MD Anderson License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson, including technologies relating to novel CAR + T-cell co-exclusive non-exclusive in-process

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation The Company recognized stock-based compensation expense on all employee and non-employee For the three months For the nine months ended September 30, (in thousands) 2017 2016 2017 2016 Research and development $ 615 $ 505 $ 1,772 $ 1,398 General and administrative 1,467 1,514 4,393 4,696 Stock-based compensation expense $ 2,082 $ 2,019 $ 6,165 $ 6,094 The Company granted 593,500 and 859,000 stock options during the three and nine months ended September 30, 2017 with a weighted-average grant date fair value of $4.29 and $4.34 per share, respectively. The Company granted an aggregate of 21,300 and 157,300 stock options during the three and nine months ended September 30, 2016 with a weighted-average grant date fair value of $3.71 and $5.36 per share, respectively. For the three months ended September 30, 2017 and 2016, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions: For the three months ended September 30, 2017 2016 Risk-free interest rate 1.88 - 2.01% 1.27 - 1.37% Expected life in years 6 6 Expected volatility 80.82 - 80.95% 79.26 - 79.34% Expected dividend yield 0 0 The Company adopted ASU 2016-09 Stock Compensation Improvement to Employee Share-Based Payment Accounting 2016-09, Stock option activity under the Company’s stock option plan for the nine months ended September 30, 2017 is as follows: Number of Weighted- Weighted- Aggregate Outstanding, December 31, 2016 3,465,335 $ 5.07 Granted 359,000 6.28 Exercised (80,000 ) 4.85 Cancelled (122,000 ) 6.64 Outstanding, September 30, 2017 3,622,335 $ 5.14 6.22 $ 5,657 Options exercisable, September 30, 2017 2,696,835 $ 4.62 5.39 $ 5,215 Options exercisable, December 31, 2016 2,671,835 $ 4.40 5.88 $ 3,383 Options available for future grant 1,540,760 At September 30, 2017, total unrecognized compensation costs related to unvested stock options outstanding amounted to $5.0 million. The cost is expected to be recognized over a weighted-average period of 1.71 years. In September 2017, the Company granted an option for 500,000 shares of its common stock, with an exercise price of $6.16 per share, and vesting one third on the next three grant date anniversaries. This option was granted outside of the 2012 plan and therefore, is not included in the table above. The grant date fair value was $2.2 million. As of September 30, 2017, all 500,000 options are outstanding with a remaining contractual life of 10.0 years. A summary of the status of unvested restricted stock for the nine months ended September 30, 2017 is as follows: Number of Shares Weighted-Average Non-vested, 1,680,492 $ 7.49 Granted — — Vested (350,000 ) 9.35 Cancelled — — Non-vested, 1,330,492 $ 9.46 At September 30, 2017, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $6.0 million. The cost is expected to be recognized over a weighted-average period of 1.33 years.

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Preferred Stock	9. Preferred Stock The Company has 30,000,000 shares of preferred stock authorized, of which, 250,000 shares are designated as Series 1 preferred stock. On June 29, 2016, the Company entered into the 2016 ECP Amendment and 2016 GvHD Amendment with Intrexon (Note 6). In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company issued to Intrexon 100,000 shares of its newly designated Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization. The Series 1 preferred stock has the following rights and preferences and certain other rights, preferences, privileges and obligations. Conversion All shares of Series 1 preferred stock shall automatically convert into shares of common stock upon the public announcement of the first approval in the United States of (i) a ZIOPHARM Product under the Channel Agreement, (ii) a Product under the GvHD Agreement or (iii) a Product under the Ares Trading Agreement, which the Company refers to as the Conversion Event Date. On the second business day following the Conversion Event Date, each of Series 1 preferred stock shall convert into a number of shares of common stock equal to the stated value of such Series 1 preferred stock, divided by the greater of (i) the volume weighted average closing price of common stock as reported by The Nasdaq Stock Market, LLC over the 20 trading days ending on the Conversion Event Date or (ii) $1.00 per share; however, without shareholder approval in accordance with the NASDAQ Listing Rules, the Company will not affect any conversion of the Series 1 preferred stock into shares of common stock in excess of 19.9% of the lesser of (i) the pre-transaction Dividends The Series 1 preferred stock provides for a monthly dividend, payable in additional shares of Series 1 preferred stock, equal to $12.00 per share, per month divided by the stated value per share, or the PIK Dividend; provided, that if any shares of Series 1 preferred stock are not converted on the Conversion Event Date (discussed below), then the rate of the PIK Dividend on all remaining unconverted shares of Series 1 preferred stock shall automatically increase from $12.00 to $24.00 per share, per month. Liquidation Value In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a change of control or sale, lease transfer or exclusive license of all or substantially all of the Company’s assets prior to the conversion of the Series 1 preferred stock into shares of common stock, then the Series 1 preferred stock will participate in the proceeds of the transaction on a pro rata basis along with common stock, treating the Series 1 preferred stock as if it had been converted into a number of shares of common stock equal to the aggregate stated value of the Series 1 preferred stock, divided by the volume weighted average closing price of common stock over the 20 trading days ending on the public announcement of such voluntary or involuntary liquidation, dissolution or winding up of the Company or change of control or sale, lease transfer or exclusive license of all or substantially all of the Company’s assets. Alternatively, the Company may redeem the Series 1 preferred stock at a redemption price equal to the pro rata amount that the Series 1 preferred stock would have received if it had been converted using the same formula. Voting Rights The Series 1 preferred stock does not have any voting rights except that the Company may not, without the consent of the holders of a majority of the outstanding shares of the Series 1 preferred stock, voting as a separate class, (i) amend, alter or repeal any provision of its Certificate of Incorporation in a manner that adversely affects the powers, preferences or rights of the Series 1 preferred stock in a manner that is more adverse than the effect on any other class or series of the Company’s capital stock; (ii) (A) create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of the Company’s capital stock unless the same ranks junior or pari passu to the Series 1 preferred stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends and rights of redemption, or (B) reclassify, alter or amend any existing security that is junior or pari passu to the Series 1 preferred stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Series 1 preferred in respect of any such right, preference or privilege; or (iii) enter into any transaction (or series of related transactions) the effect of which would adversely affect the holders of the Series 1 preferred stock in a manner that is more adverse than the effect on any other class or series of capital stock. Analysis The Company analyzed the features of the Series 1 preferred stock and determined that the conversion option and the Company’s right to redeem the shares at liquidation are embedded derivatives that required bifurcation from the Series 1 preferred stock in accordance with FASB ASC 815, Derivatives and Hedging During the three months ended September 30, 2017, the Company issued an aggregate of 3,414 shares of Series 1 preferred stock to Intrexon, the holder of all of the outstanding shares of its Series 1 preferred stock, as monthly dividend payments. The Company recorded such shares of Series 1 preferred stock at a fair value of $4.9 million, which is a component of temporary equity and recorded a gain on the change in fair value of the derivative liabilities in the amount of $202 thousand (Note 10).

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	10. Derivative Financial Instruments The Company determined that certain embedded features related to the Series 1 preferred stock are derivative financial instruments. Fair values of derivative instruments to be classified as derivative liabilities on the balance sheet consist of the following: ($ in thousands) Liability derivates: Balance Sheet Location Fair Value September 30, 2017: Derivative liabilities Liabilities $ 2,350 The change in the derivative liability for the three months ended September 30, 2017 consisted of the following: ($ in thousands) Fair Value Balance, June 30, 2017 $ 2,480 Dividends 72 Change in fair value of derivative liabilities (202 ) Balance, September 30, 2017 $ 2,350 The fair value of the Series 1 preferred stock dividends were estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change and that change could be material. Inputs to the models included the following: September 30, 2017 December 31, 2016 Risk-free interest rate 1.72 % 1.69 % Expected dividend rate 0 0 Expected volatility 70.20 % 72.70 % Preferred stock conversion limit - percentage of outstanding common stock 19.90 % 19.90 % Preferred conversion floor price $ 1.00 $ 1.00 See Notes 4 and 9 for additional discussion regarding the accounting for and valuation of these derivative financial instruments.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued ASU 2014-09, Revenue from Contracts with Customers 2014-09”), In February 2016, the FASB issued ASU No. 2016-02, Leases 2016-02. Leases In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Accounting 2016-09, 2016-09 2016-09, In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments 2016-15, 2016-15 In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows Restricted Cash 2016-18, In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation Scope of Modification Accounting 2017-09, 2017-09

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 and December 31, 2016 were as follows: ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 79,488 $ 79,488 $ — $ — Liabilities: Derivative liabilities $ (2,350 ) $ — $ — $ (2,350 ) ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 77,120 $ 77,120 $ — $ — Liabilities: Derivative liabilities $ (862 ) $ — $ — $ (862 )

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and preferred stock, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potentially dilutive shares of common stock at September 30, 2017 and 2016 consisted of the following: September 30, 2017 2016 Stock options 3,622,335 3,448,070 Unvested restricted stock 1,330,492 1,236,388 Preferred stock 22,398,582 22,564,685 27,351,409 27,249,143

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expense on All Employee and Non-Employee Awards	The Company recognized stock-based compensation expense on all employee and non-employee For the three months For the nine months ended September 30, (in thousands) 2017 2016 2017 2016 Research and development $ 615 $ 505 $ 1,772 $ 1,398 General and administrative 1,467 1,514 4,393 4,696 Stock-based compensation expense $ 2,082 $ 2,019 $ 6,165 $ 6,094
Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model	For the three months ended September 30, 2017 and 2016, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions: For the three months ended September 30, 2017 2016 Risk-free interest rate 1.88 - 2.01% 1.27 - 1.37% Expected life in years 6 6 Expected volatility 80.82 - 80.95% 79.26 - 79.34% Expected dividend yield 0 0
Stock Option Activity Under Stock Option Plan	Stock option activity under the Company’s stock option plan for the nine months ended September 30, 2017 is as follows: Number of Weighted- Weighted- Aggregate Outstanding, December 31, 2016 3,465,335 $ 5.07 Granted 359,000 6.28 Exercised (80,000 ) 4.85 Cancelled (122,000 ) 6.64 Outstanding, September 30, 2017 3,622,335 $ 5.14 6.22 $ 5,657 Options exercisable, September 30, 2017 2,696,835 $ 4.62 5.39 $ 5,215 Options exercisable, December 31, 2016 2,671,835 $ 4.40 5.88 $ 3,383 Options available for future grant 1,540,760
Summary of Unvested Restricted Stock	A summary of the status of unvested restricted stock for the nine months ended September 30, 2017 is as follows: Number of Shares Weighted-Average Non-vested, 1,680,492 $ 7.49 Granted — — Vested (350,000 ) 9.35 Cancelled — — Non-vested, 1,330,492 $ 9.46

Derivative Financial Instrume23

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments to be classified as Derivative Liabilities on Balance Sheet	Fair values of derivative instruments to be classified as derivative liabilities on the balance sheet consist of the following: ($ in thousands) Liability derivates: Balance Sheet Location Fair Value September 30, 2017: Derivative liabilities Liabilities $ 2,350
Change in Derivative Liability	The change in the derivative liability for the three months ended September 30, 2017 consisted of the following: ($ in thousands) Fair Value Balance, June 30, 2017 $ 2,480 Dividends 72 Change in fair value of derivative liabilities (202 ) Balance, September 30, 2017 $ 2,350
Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model	The fair value of the Series 1 preferred stock dividends were estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change and that change could be material. Inputs to the models included the following: September 30, 2017 December 31, 2016 Risk-free interest rate 1.72 % 1.69 % Expected dividend rate 0 0 Expected volatility 70.20 % 72.70 % Preferred stock conversion limit - percentage of outstanding common stock 19.90 % 19.90 % Preferred conversion floor price $ 1.00 $ 1.00

Business - Additional Informati

Business - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Accumulated deficit	$ (699,169)	$ (657,997)
Cash and cash equivalents	$ 84,406	$ 81,053	$ 94,683	$ 140,717

Financings - Additional Informa

Financings - Additional Information (Detail) $ / shares in Units, $ in Millions	May 11, 2017USD ($)$ / sharesshares
Banking and Thrift [Abstract]
Stock issued during period | shares	9,708,738
Issuance & sale of common stock in public offering price per share	$ 5.15
Sale of stock price per share	$ 4.893
Net proceeds from issuance of common stock | $	$ 47.3

Assets and Liabilities Measured

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Assets:
Cash equivalents	$ 79,488	$ 77,120
Liabilities:
Derivative liabilities	(2,350)	(862)
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Assets:
Cash equivalents	79,488	77,120
Significant Unobservable Inputs (Level 3)
Liabilities:
Derivative liabilities	$ (2,350)	$ (862)

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - shares	Jun. 29, 2016	Sep. 30, 2017
Intrexon Corporation | Series 1 Preferred Stock
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Issuance of stock in a license agreement (in shares)	100,000	3,414

Potential Dilutive Shares Exclu

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	27,351,409	27,249,143
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	3,622,335	3,448,070
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,330,492	1,236,388
Series 1 Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	22,398,582	22,564,685

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Detail) - Intrexon Corporation	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Earnings Loss Per Share [Line Items]
Agreement start date	Jan. 6, 2011
Series 1 Preferred Stock
Earnings Loss Per Share [Line Items]
Number of shares converted into common stock | shares	22,398,582
Preferred stock, conversion rate | $ / shares	$ 1

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)

Jun. 29, 2016$ / sharesshares

Sep. 28, 2015USD ($)

Jan. 13, 2015USD ($)shares

Jan. 09, 2015USD ($)shares

Mar. 07, 2011USD ($)

Jan. 06, 2011

Aug. 24, 2004Patent

Nov. 30, 2017USD ($)

Sep. 30, 2015USD ($)

Jul. 31, 2015USD ($)

Sep. 30, 2017USD ($)$ / sharesshares

Sep. 30, 2016USD ($)

Sep. 30, 2017USD ($)$ / sharesshares

Sep. 30, 2016USD ($)

Dec. 31, 2015USD ($)shares

Dec. 31, 2013USD ($)

Dec. 31, 2012

Dec. 31, 2011USD ($)

Jan. 10, 2017USD ($)

Dec. 31, 2016USD ($)$ / shares

Mar. 31, 2016USD ($)

May 31, 2015USD ($)

Dec. 31, 2014USD ($)shares

Commitments and Contingencies Disclosure [Line Items]

Total rent Expense

$ 177,000

$ 109,000

$ 545,000

$ 231,000

Deferred rent - current portion

166,000

166,000

$ 155,000

Deferred rent-non-current portion

14,000

14,000

126,000

Deferred rent liability net

180,000

180,000

281,000

Research and Development Expense

11,105,000

8,975,000

$ 33,903,000

148,402,000

Research and development arrangement Terms

Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.

Research and Development Service Agreement Aggregate Quarterly Payments

$ 9,300,000

11,300,000

Offset costs in research and development expense

6,200,000

Deferred revenue - current portion

6,389,000

6,389,000

6,389,000

Deferred Revenue, long term

36,736,000

$ 36,736,000

41,528,000

The University of Texas MD Anderson Cancer Center and The Texas A & M University System

Commitments and Contingencies Disclosure [Line Items]

Milestone maximum payment

$ 4,500,000

Number of products | Patent

2

Options to purchase common stock | shares

50,222

Shares vested | shares

37,666

The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Research and Development Expense

Commitments and Contingencies Disclosure [Line Items]

Issuance of common stock in a license agreement

$ 87,000

The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Upon enrollment of the first patient in a multi-center pivotal clinical trial

Commitments and Contingencies Disclosure [Line Items]

Shares vested | shares

12,556

Solasia

Commitments and Contingencies Disclosure [Line Items]

Upfront payment received

$ 5,000,000

Milestone payment received

$ 1,000,000

Miles stone payment payable

$ 1,000,000

Solasia | Development-based milestones

Commitments and Contingencies Disclosure [Line Items]

Expected Additional milestone payments to be received

32,500,000

Solasia | Sales-based milestones

Commitments and Contingencies Disclosure [Line Items]

Expected Additional milestone payments to be received

53,500,000

Baxter Healthcare Corporation | Upon the successful U.S. IND application for indibulin

Commitments and Contingencies Disclosure [Line Items]

Installment payments

0

0

Baxter Healthcare Corporation | Upon the successful U.S. IND application for indibulin | Scenario, Forecast

Commitments and Contingencies Disclosure [Line Items]

Additional payment payable amount

$ 250,000

License Agreement

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

$ 67,300,000

$ 67,300,000

Issuance of common stock in licensing agreement, shares | shares

11,722,163

11,722,163

ARES Trading License

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

718,000

$ 994,000

Agreement termination, notice period

90 days

Milestone payments, percentage

50.00%

Agreement commencement date

2015-05

Deferred revenue, revenue recognized

1,600,000

$ 1,600,000

$ 1,600,000

$ 1,600,000

Deferred revenue, upfront payment

$ 43,100,000

$ 43,100,000

$ 47,900,000

$ 57,500,000

Minimum

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

$ 15,000,000

Maximum

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

20,000,000

Series 1 Preferred Stock

Commitments and Contingencies Disclosure [Line Items]

Preferred stock, stated value | $ / shares

$ 1,200

$ 1,200

$ 1,200

Prepaid Expenses and Other Current Assets

Commitments and Contingencies Disclosure [Line Items]

Pre paid research and development expenses

$ 29,400,000

$ 29,400,000

Development Milestone Payments | ARES Trading License

Commitments and Contingencies Disclosure [Line Items]

Payments for development, regulatory and commercial milestones per Product

60,000,000

Regulatory Milestone Payments | ARES Trading License

Commitments and Contingencies Disclosure [Line Items]

Payments for development, regulatory and commercial milestones per Product

148,000,000

Commercial Milestone Payments | ARES Trading License

Commitments and Contingencies Disclosure [Line Items]

Payments for development, regulatory and commercial milestones per Product

205,000,000

Substantive Milestones

Commitments and Contingencies Disclosure [Line Items]

Potential milestone payment

15,000,000

$ 15,000,000

Intrexon Corporation

Commitments and Contingencies Disclosure [Line Items]

Contract termination description

The Company's obligation to pay 20% of net profits or revenue described above with respect to these "retained" products will survive termination of the Channel Agreement.

Licensing fee

$ 10,000,000

$ 115,000,000

Milestone payment receivable

$ 5,000,000

Milestone payment receivable period

2 years

Upfront payment received

$ 57,500,000

Percentage of upfront fee Payable

50.00%

Milestone maximum payment

$ 50,000,000

$ 50,000,000

Intrexon Corporation | 2016 GvHD Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

20.00%

Contract termination description

The Company's obligation to pay 20% of net profits or revenue with respect to these "retained" products will survive termination of the GvHD Agreement.

Licensing fee

$ 10,000,000

Research and Development Expense

$ 10,000,000

Agreement termination period

24 months

Agreement termination, notice period

90 days

Intrexon Corporation | License Agreement

Commitments and Contingencies Disclosure [Line Items]

Cash consideration for license agreement

$ 50,000,000

Intrexon Corporation | Letter Agreement

Commitments and Contingencies Disclosure [Line Items]

Cash consideration for license agreement

$ 7,500,000

Intrexon Corporation | Cooperative Research and Development Agreement | National Cancer Institute

Commitments and Contingencies Disclosure [Line Items]

Obligation for payment

$ 5,600,000

Miles stone payment payable

$ 625,000

Milestone payment paid

$ 1,900,000

Intrexon Corporation | Quarterly Payment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

20.00%

Percentage of revenue agreed to pay which is obtained from sublicensor

50.00%

Intrexon Corporation | Quarterly Payment | 2016 GvHD Amendment | After Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

20.00%

Intrexon Corporation | Quarterly Payment | 2016 GvHD Amendment | Before Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

50.00%

Intrexon Corporation | Quarterly Payment | ECP Channel Agreement | After Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

20.00%

Intrexon Corporation | Quarterly Payment | ECP Channel Agreement | Before Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

50.00%

Intrexon Corporation | Series 1 Preferred Stock

Commitments and Contingencies Disclosure [Line Items]

Issuance of common stock in licensing agreement, shares | shares

100,000

3,414

Preferred stock, stated value | $ / shares

$ 1,200

ZIOPHARM | License Agreement

Commitments and Contingencies Disclosure [Line Items]

Common stock issued for cash | shares

10,124,561

Cash consideration for license agreement

$ 50,000,000

ZIOPHARM | Letter Agreement

Commitments and Contingencies Disclosure [Line Items]

Common stock issued for cash | shares

1,597,602

Cash consideration for license agreement

$ 7,500,000

New York, NY

Commitments and Contingencies Disclosure [Line Items]

Letter of credit

$ 388,000

388,000

$ 388,000

Operating lease expiration month and year

2018-10

Loss on sublease

$ 729,000

Obligation for payment

2,300,000

Sublease revenue from subtenant

$ 1,600,000

Boston, MA

Commitments and Contingencies Disclosure [Line Items]

Operating lease expiration month and year

2016-08

Security deposits

$ 128,000

$ 128,000

$ 128,000

Sublease term amendment

Aug. 31, 2021

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	May 11, 2017	Jun. 29, 2016	Jan. 08, 2016	Sep. 28, 2015	Jun. 29, 2015	Mar. 27, 2015	Feb. 03, 2015	Jan. 06, 2011	Sep. 30, 2015	Jul. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2016
Related Party Transaction [Line Items]
Stock issued during period	9,708,738
Commitment to purchase common stock														$ 2
Stock buy back													$ 1,042
Change in fair value of derivative liability											$ 202	$ 21	(1,292)	21
Research and Development Expense											$ 11,105	8,975	33,903	148,402
Research and Development Service Agreement Aggregate Quarterly Payments													9,300	11,300
Research and Development Service Agreement Aggregate Quarterly Payments													$ 35,600
Series 1 Preferred Stock
Related Party Transaction [Line Items]
Preferred stock, stated value											$ 1,200		$ 1,200			$ 1,200
Temporary equity, fair value											$ 4,900		$ 4,900
License Agreement
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)													11,722,163		11,722,163
Research and Development Expense													$ 67,300		$ 67,300
Intrexon Corporation
Related Party Transaction [Line Items]
Stock issued during period							1,440,000
Percentage of commitment for payments from receipts of upfronts, milestones and royalties						50.00%
Commitment to purchase common stock						$ 43,500		$ 50,000
Stock buy back (Shares)					3,711
Stock buy back					$ 34
Share buy back discount on closing price					5.00%
Company re-purchased additional shares			168
Company re-purchased additional shares Value			$ 2
Licensing fee				$ 10,000						$ 115,000
Amounts expensed for services incurred											5,600	$ 4,900	16,800	$ 17,000
Amount due to related party, current											$ 5,500		$ 5,500			$ 3,400
Intrexon Corporation | Series 1 Preferred Stock
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)		100,000									3,414
Preferred stock, stated value		$ 1,200
Dividends, preferred stock		$ 12
Intrexon Corporation | 2016 GvHD Amendment
Related Party Transaction [Line Items]
Licensing fee				$ 10,000
Royalty percentage of net profit													20.00%
Research and Development Expense									$ 10,000
Intrexon Corporation | Quarterly Payment
Related Party Transaction [Line Items]
Royalty percentage of net profit								20.00%
Intrexon Corporation | Quarterly Payment | ECP Channel Agreement | After Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit		20.00%
Intrexon Corporation | Quarterly Payment | ECP Channel Agreement | Before Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit		50.00%
Intrexon Corporation | Quarterly Payment | 2016 GvHD Amendment | After Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit		20.00%
Intrexon Corporation | Quarterly Payment | 2016 GvHD Amendment | Before Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit		50.00%

Stock-Based Compensation Expens

Stock-Based Compensation Expense Included in Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 2,082	$ 2,019	$ 6,165	$ 6,094
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	615	505	1,772	1,398
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,467	$ 1,514	$ 4,393	$ 4,696

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted		593,500	21,300	859,000	157,300
Weighted-average grant date fair value		$ 4.29	$ 3.71	$ 4.34	$ 5.36
Stock options granted exercise price				$ 6.28
Stock options outstanding	3,622,335	3,622,335		3,622,335		3,465,335
Stock options remaining contractual life				6 years 2 months 19 days
Outside 2012 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted	500,000
Stock options granted exercise price	$ 6.16
Share Based compensation arrangement by share based payment award options grants grant date fair value	$ 2,200	$ 2,200		$ 2,200
Stock options outstanding	500,000	500,000		500,000
Stock options remaining contractual life	10 years
Outside 2012 Plan | The next three grant date anniversaries vesting percentage
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, award vesting rights, percentage	33.33%
Accounting Standards Update 2016-09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cumulative effect adjustment	$ (122)	$ (122)		$ (122)
Unvested Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to unvested restricted stock outstanding	5,000	5,000		$ 5,000
Expected recognition period				1 year 8 months 16 days
Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected recognition period				1 year 3 months 29 days
Unrecognized stock-based compensation expense related to unvested restricted stock	$ 6,000	$ 6,000		$ 6,000

Fair Value of Stock Options Ass

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate, Minimum	1.88%	1.27%
Risk-free interest rate, Maximum	2.01%	1.37%
Expected life in years	6 years	6 years
Expected volatility, Minimum	80.82%	79.26%
Expected volatility, Maximum	80.95%	79.34%
Expected dividend yield	0.00%	0.00%

Stock Option Activity Under Sto

Stock Option Activity Under Stock Option Plan (Detail) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Number of Shares
Beginning Balance	3,465,335
Granted	359,000
Exercised	(80,000)
Cancelled	(122,000)
Ending Balance	3,622,335	3,465,335
Options exercisable, at end of period	2,696,835	2,671,835
Options available for future grant	1,540,760
Weighted Average Exercise Price
Beginning Balance | $ / shares	$ 5.07
Granted | $ / shares	6.28
Exercised | $ / shares	4.85
Cancelled | $ / shares	6.64
Ending Balance | $ / shares	5.14	$ 5.07
Options exercisable, at end of period | $ / shares	$ 4.62	$ 4.40
Weighted Average Contractual Term (Years)
Outstanding, at end of period	6 years 2 months 19 days
Options exercisable, at end of period	5 years 4 months 20 days	5 years 10 months 17 days
Aggregate Intrinsic Value
Outstanding, at end of period | $	$ 5,657
Options exercisable, at end of period | $	$ 5,215	$ 3,383

Summary of Unvested Restricted

Summary of Unvested Restricted Stock (Detail) - Unvested Restricted Common Stock	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Number of Shares
Beginning Balance | shares	1,680,492
Granted | shares	0
Vested | shares	(350,000)
Cancelled | shares	0
Ending Balance | shares	1,330,492
Weighted Average Grant Date Fair Value
Beginning Balance | $ / shares	$ 7.49
Granted | $ / shares	0
Vested | $ / shares	9.35
Cancelled | $ / shares	0
Ending Balance | $ / shares	$ 9.46

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jun. 29, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Jul. 01, 2016
Preferred Stock [Line Items]
Preferred stock, shares authorized		30,000,000		30,000,000		30,000,000
Change in fair value of derivative liability		$ 202	$ 21	$ (1,292)	$ 21
Series 1 Preferred Stock
Preferred Stock [Line Items]
Preferred stock, shares authorized		250,000		250,000
Preferred stock, shares issued		116,127		116,127		106,184
Preferred stock, stated value		$ 1,200		$ 1,200		$ 1,200
Maximum percentage of common stock issuable upon conversion of preferred stock				19.90%		19.90%
Fair value of Series 1 preferred stock as a component of temporary equity		$ 139,065		$ 139,065		$ 125,321
Temporary equity, fair value		4,900		4,900
Intrexon Corporation
Preferred Stock [Line Items]
Embedded conversion liability		$ 700		$ 700
Fair value of Series 1 preferred stock as a component of temporary equity							$ 118,400
Intrexon Corporation | Series 1 Preferred Stock
Preferred Stock [Line Items]
Preferred stock, shares issued	100,000	3,414		3,414
Preferred stock, stated value	$ 1,200
Preferred stock, conversion rate				$ 1
Maximum percentage of common stock issuable upon conversion of preferred stock				19.90%
Preferred stock monthly dividend payable (per share)	$ 12
Intrexon Corporation | Series 1 Preferred Stock | Before Conversion Event Date
Preferred Stock [Line Items]
Preferred stock monthly dividend payable (per share)				$ 12
Intrexon Corporation | Series 1 Preferred Stock | Remaining Unconverted Shares
Preferred Stock [Line Items]
Preferred stock monthly dividend payable (per share)				$ 24

Fair Values of Derivative Instr

Fair Values of Derivative Instruments to be classified as Derivative Liabilities on Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 2,350	$ 2,480
Liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 2,350

Change in Derivative Liability

Change in Derivative Liability (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Balance, June 30, 2017	$ 2,480
Dividends	72
Change in fair value of derivative liabilities	(202)	$ (21)	$ 1,292	$ (21)
Balance, September 30, 2017	$ 2,350		$ 2,350

Fair Value Assumptions Used in

Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model (Detail) - Series 1 Preferred Stock - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Derivatives, Fair Value [Line Items]
Risk-free interest rate	1.72%	1.69%
Expected dividend rate	0.00%	0.00%
Expected volatility	70.20%	72.70%
Preferred stock conversion limit - percentage of outstanding common stock	19.90%	19.90%
Preferred conversion floor price	$ 1	$ 1